COGT Stock — Cogent Biosciences Inc.: Cash, EV, Pipeline

Share price

$32.52

Market cap

$5,639.6M

Cash

$792.3M

Enterprise value

$5,070.8M

Balance sheet

Cash	$792.3M
Debt	$223.5M
Net cash	$568.8M
Enterprise value	$5,070.8M
Basic shares	171.6M shares
Fully diluted shares	232.5M shares
Fully diluted market cap	$7,561.1M
Cash per share	$4.62

Cash figures as of 2026-06-30. Database snapshot: 2026-09-22.

Price history

Loading COGT daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Apr 12 - May 24	CGT4859	Phase 2	Intrahepatic Cholangiocarcinoma (Icc); Cholangiocarcinoma; Other Solid Tumors, Adult	—
Jun 12 - Jul 24	CGT4255	Phase 1	Advanced Solid Tumor, Adult; ERBB2 Altered Breast Cancer; ERBB2 Gene Amplification	—
Aug 12 - Sep 23	CGT6297	Phase 1	PIK3CA Mutations; Advanced Solid Tumors, Adult; Endometrial Cancer	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

Bezuclastinib

Phase 3 · Active Modality: highly selective tyrosine kinase inhibitor

Aliases CGT9486

Target KIT (KIT D816V)

Partnerships Plexxikon (Daiichi Sankyo group; exclusive worldwide license)

Indications

systemic mastocytosis (NonAdvSM, AdvSM) (Phase 3)
gastrointestinal stromal tumor (GIST, with sunitinib) (Phase 3)

Catalysts

— December 30, 2026

Status note NDAs submitted for NonAdvSM (accepted March 2026) and AdvSM (June 2026); Phase 3 PEAK trial in GIST ongoing; no discontinuation disclosed.

CGT4255

Phase 1 · Active Modality: CNS-penetrant selective mutant ErbB2 inhibitor

Target ErbB2 (mutant)

Indications

Advanced Solid Tumor, Adult (Phase 1)
ERBB2 Altered Breast Cancer (Phase 1)
ERBB2 Gene Amplification (Phase 1)

Status note Ongoing Phase 1 dose-escalation study; no discontinuation disclosed.

CGT6297

Phase 1 · Active Modality: wild-type-sparing PI3Ka inhibitor

Target PI3Ka

Indications

PIK3CA Mutations (Phase 1)
Advanced Solid Tumors, Adult (Phase 1)
Endometrial Cancer (Phase 1)

Status note Ongoing Phase 1 dose-escalation study; no discontinuation disclosed.

KRAS inhibitor

Preclinical · Active

Target KRAS

Indications

colorectal cancer (Preclinical)
non-small cell lung cancer (Preclinical)
pancreatic cancer (Preclinical)

Catalysts

— 2026

Status note Program unnamed in filing; research-stage selective KRAS inhibitor.

JAK2 V617F inhibitor

Preclinical · Active

Target JAK2 V617F

Indications

myeloproliferative neoplasms (Preclinical)

Catalysts

— 2026

Status note Program unnamed in filing; wild-type-sparing JAK2 V617F mutant-selective inhibitor.

Per-asset detail extracted from the 10-Q filed 2026-08-10. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	bezuclastinib
Lead indication	GIST 2L; NonAdvSM; AdvSM
Lead phase	NDA (3 filings)
Active trials	6
Collaborator trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT05208047	Phase 3	Recruiting	Sponsor	COGT	—	Advanced Gastrointestinal Stromal Tumors; Metastatic Cancer	—
NCT06777316	Phase 2	Active, not recruiting	Sponsor	COGT	—	Intrahepatic Cholangiocarcinoma (Icc); Cholangiocarcinoma; Other Solid Tumors, Adult	—
NCT05186753	Phase 2	Active, not recruiting	Sponsor	COGT	—	SSM; Mastocytosis, Indolent; Mastocytosis, Systemic	—
NCT04996875	Phase 2	Recruiting	Sponsor	COGT	—	Advanced Systemic Mastocytosis (AdvSM); SM With an Associated Hematologic Neoplasm (SM-AHN); Mast Cell Leukemia (MCL)	—
NCT07361562	Phase 1	Recruiting	Sponsor	COGT	—	Advanced Solid Tumor, Adult; ERBB2 Altered Breast Cancer; ERBB2 Gene Amplification	—
NCT07383506	Phase 1	Recruiting	Sponsor	COGT	—	PIK3CA Mutations; Advanced Solid Tumors, Adult; Endometrial Cancer	—
NCT06208748	Phase 2	Active, not recruiting	Collaborator	Sarcoma Alliance for Research through Collaboration	—	Gastrointestinal Stromal Tumors; GIST	—

Sponsor-matched active trials from ClinicalTrials.gov (6 as sponsor, 1 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 7 active trials for Cogent Biosciences, Inc. on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
OrbiMed Advisors	2,681,300	+1,359,200	1.26%	2026-08-14
RTW Investments	2,309,021	-3,149,654	0.76%	2026-08-14
Logos Global Management	900,000	+900,000	1.50%	2026-08-14
Sphera Biotech	459,340	+43,000	2.54%	2026-08-14
Ikarian Capital	370,084	+370,084	2.34%	2026-08-14
ADAR1 Capital Management	12,200	+12,200	0.02%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

COGT — Cogent Biosciences Inc.

Balance sheet

Price history

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Institutional holders